Search PubMed⌕ Search

Biomedical subjects

A Victor

Publications and source records attributed to A Victor.

71 records · Page 4Linked to original sources
PubMed1977

Relation between sex hormone binding globulin and D-norgestrel levels in plasma.

In order to investigate the effect of changes in sex hormone binding globulin (SHBG) levels on d-norgestrel (d-Ng) levels in plasma, the plasma levels of SHBG and d-Ng were studied during one treatment cycle in 6 women on oral contraceptives containing d-Ng and ethinyloestradiol (EOE2) and in 3 women using subcutaneous silastic rods containing d-Ng concomitantly taking EOe2 for three weeks. A significant positive correlation between the SHBG and d-Ng levels was found in 7 of the 9 subjects studied. The results provide evidence for an in vivo binding of d-Ng to SHBG, a SHBG influence on the metabolic clearance rate of d-Ng and consequently a dependence of the plasma levels of d-Ng on the SHBG concentrations in the plasma. These findings support the concept that the clinically and biochemically observed anti-oestrogenic/androgenic effects observed in women on d-Ng containing medication are due to a displacement of testosterone from SHBG by d-Ng.

Contraceptives, Oral, Combined↗
PubMed1976

Sex hormone binding globulin: the carrier protein for d-norgestrel.

The binding of different synthetic steroids, used in hormonal contraception, to Sex Hormone Binding Globulin (SHBG) was studied by measuring their ability to displace tritiated testosterone from SHBG in a competitive protein binding system. Only 19-nortestosterone derivates had any significant ability to displace testosterone from SHBG, d-norgestrel (d-Ng) being the strongest displacer. Increasing the SHBG levels in women with previous constant plasma d-Ng levels increased these levels two- to sixfold. It is concluded that SHBG is the main carrier protein for d-Ng. The strong testosterone displacing activity of d-Ng might also explain androgenic side effects observed with d-Ng containig oral contraceptives.

Acne Vulgaris↗
PubMedDate not supplied

New York State screening program for fragile X syndrome: a progress report.

New York State has established a program to screen post-pubertal mentally retarded males for the fragile X [fra(X)] syndrome. The goal of the program is to identify affected males and inform their families of the diagnosis. Females in these families who are at risk for inheriting the mutation will then be able to determine their carrier status and consider that information in making reproductive decisions. Males were evaluated for 10 features of the syndrome by physicians and nurses throughout the state; cytogenetic analysis was carried out on a subset of this population. A total of 1332 males has been screened and chromosome studies have been completed for 489. Forty-three (9%) were positive for fra(X), and an additional 11 other chromosome abnormalities were identified. The 43 patients belonged to 38 families. Of the 24 families who were informed of the diagnosis, 12 consulted genetic counseling centers for follow-up studies and 12 did not.

Adult↗